We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Intelligent Ultrasound Group Plc | LSE:IUG | London | Ordinary Share | GB00BN791Q39 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.45 | 5.14% | 9.20 | 208,921 | 16:35:21 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 8.50 | 9.20 | 9.10 | 8.75 | 8.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Electromedical Apparatus | 10.1M | -2.98M | -0.0091 | -9.73 | 28.93M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:21 | UT | 10,005 | 9.20 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 19/4/2024 | 11:41 | ALNC |  Intelligent Ultrasound launches GE AI software on ultrasound machines |
| 19/4/2024 | 07:00 | UK RNS | Intelligent Ultrasound Group PLC Sonolyst launched on Voluson Signature.. |
| 19/4/2024 | 07:00 | UK RNS | Intelligent Ultrasound Group PLC Notice of Results |
| 29/2/2024 | 14:24 | ALNC | TRADING UPDATES: Itim revenue up 15%; Aminex completes seismic dataset |
| 29/2/2024 | 07:00 | UK RNS | Intelligent Ultrasound Group PLC NHS Scotland Adopts Classroom to Clinic.. |
| 27/2/2024 | 21:12 | ALNC | TRADING UPDATES: Armadale Capital eyes Mahenge project financing |
| 27/2/2024 | 15:45 | UK RNS | Intelligent Ultrasound Group PLC ScanNav FetalCheck Used in Trial Study |
| 09/2/2024 | 09:18 | ALNC | Intelligent Ultrasound launches portable needling training simulator |
| 09/2/2024 | 07:00 | UK RNS | Intelligent Ultrasound Group PLC Launch of Portable NeedleTrainer Plus |
| 09/1/2024 | 14:16 | ALNC | TAKING AIM: Analysts "remain positive" as Intelligent Ultrasound grows |
Intelligent Ultrasound (IUG) Share Charts1 Year Intelligent Ultrasound Chart |
|
1 Month Intelligent Ultrasound Chart |
Intraday Intelligent Ultrasound Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 25/4/2024 | 08:32 | Intelligent Ultrasound. Clinical AI software | 432 |
| 26/4/2023 | 09:27 | Intelligent Ultrasound Group | 113 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 15:35:21 | 9.20 | 10,005 | 920.46 | UT |
| 14:46:01 | 8.68 | 100,000 | 8,681.10 | O |
| 14:36:17 | 8.61 | 1,353 | 116.49 | O |
| 13:49:04 | 8.50 | 1,811 | 153.94 | O |
| 13:00:21 | 9.20 | 19,995 | 1,839.54 | UT |
| Top Posts |
|---|
Posted at 25/4/2024 09:20 by Intelligent Ultrasound Daily Update Intelligent Ultrasound Group Plc is listed in the Electromedical Apparatus sector of the London Stock Exchange with ticker IUG. The last closing price for Intelligent Ultrasound was 8.75p.Intelligent Ultrasound currently has 326,869,921 shares in issue. The market capitalisation of Intelligent Ultrasound is £28,927,988. Intelligent Ultrasound has a price to earnings ratio (PE ratio) of -9.73. This morning IUG shares opened at 8.75p |
Posted at 19/4/2024 07:07 by bamboo2 Notice of resultsAnalyst and investor briefing Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in AI software and simulation, announces it will issue its audited final results for the year ended 31 December 2023 on Wednesday, 1 May 2024. A briefing for analysts will be held via Teams on 1 May 2024 at 9.30am. To register, please contact intelligentultrasoun The Company will host a live presentation for investors given by CEO Stuart Gall and CFO Helen Jones via the Investor Meet Company platform on Wednesday, 1 May at 1pm. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet the Company via: Investors who already follow Intelligent Ultrasound on the Investor Meet Company platform will automatically be invited. |
Posted at 19/4/2024 07:05 by bamboo2 SonoLyst, powered by Intelligent Ultrasound's ScanNav AI, launches on new GE HealthCare Voluson Signature Series ultrasound machinesIntelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company specialising in AI software and simulation, announces that GE HealthCare's SonoLyst software, powered by Intelligent Ultrasound's ScanNav AI, has been launched on the new Voluson Signature Series portfolio of ultrasound machines, the Signature 20 and Signature 18. SonoLystlive enhances ultrasound image recognition by automatically capturing images in real-time, as the clinician scans a mid-trimester patient. Using practice guidelines from the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the AI software automatically recognises the anatomy, captures the image and checks it off the list of required views. By minimising the need to manually freeze, annotate and store images, the software reduces keystrokes by up to 65% and exam time by up to 40% for sonographers. SonoLystlive will be offered as a standard feature on the Voluson Signature 20 and as an option on the Voluson Signature 18. Stuart Gall, CEO of Intelligent Ultrasound, commented: "We are pleased that with this launch, SonoLyst, powered by our ScanNav AI software, is now available on three GE HealthCare ultrasound machine ranges -- Expert, Signature and SWIFT. GE HealthCare is leading the way in using AI software to improve obstetric workflows for the benefit of clinicians and patients, while saving scanning time and destressing the scanning environment for sonographers. We remain excited that our novel 'classroom-to-clinic |
Posted at 13/4/2024 01:13 by 40 fathoms A floating charge has been registered by HSBC at Companies House. This strongly suggests that we are in the process of obtaining some form of debt facility.Firstly, I think it is very good news that a traditional lender such as HSBC sees us as creditworthy and we have clearly been able to demonstrate to them a repayment ability. At very least we will have had to demonstrate cash flow positivity in the near term. Secondly, although cash flow positivity is close at hand it will take 12 to 18 months to get to the position where we are generating sufficient levels of free cash flow to allow meaningful new investment in the business. It seems sensible to me that we would give ourselves the flexibility to accelerate investment in to the development portfolio including liver and fetalcheck and/or in to additional sales resources. The alternative would be to delay these type of investments by 12 to 18 months until the cash flows allowed it. While we still need to see the size and terms of the facility as this is HSBC they are likely to be sensible. I think this may well mark the transition of IUG from a start up to an established business. |
Posted at 08/4/2024 00:45 by 40 fathoms This news all but confirms, that at least on a run rate basis, we should reach cash flow positivity this year and should be meaningfully cash flow positive next year.Once this is confirmed, from a share price perspective, I think we enter a different paradigm. Breakeven seems to be between 16 & 17 million. The way I look at FY25 is that if we assume 10% growth in simulation sales in to FY2025 and the anticipated GE royalty revenue that takes up to breakeven. Any revenue from ScanNav PNB, Needletrainer, FetalCheck, Gestational Age & Military applications in RA will all fall to the bottom line. It is probably too early for liver products to have any impact but that has the potential to be very significant indeed, especially in light of Madrigals FDA approval of a first in class NASH drug and a encouraging results from a host of others who are one or two years behind them. |
Posted at 23/3/2024 01:13 by 40 fathoms Bamboo@ There are many positive qualities I like about IUG but one of the things that I like the me most is that they are always upgrading and adding functionality to their product range. For a small company with limited resources they do this incredibly well. I have no doubt if they get this product to market, some of the possible features you suggest and more will be added overtime. |
Posted at 19/3/2024 00:23 by gsbmba99 Interactive Investor article featuring IUG as one of five AIM growth shares for an ISA. |
Posted at 12/3/2024 23:38 by 40 fathoms @bamboo - Well found. So if we take some function of this price as a proxy for our clinical AI business, we can then use some function of Surgical Science P/E for our simulation business you are going to end up with a share price at @50p per share.Given how awful AIM is at the moment at assigning value to growth companies, by my reckoning if we receive a T/O offer this year it will be at between 20p and 25p per share. If we see decent GA licensing activity you can bump that up by 5p, proof of concept in liver another 5p (liver is worth much more but also requires significant investment) and a large DOD deal for ScanNav PNB would add 2p. A nice return but it would still leave a great deal on the table and I would prefer to see things be allowed to play out, at very least until liver is a commercial product. The question is where does the required investment for liver come from, equity, debt, partnership ? It probably needs @GBP 3.5 million to get it through trials and to market. I would be disappointed if they issued equity so I would prefer to see debt or partnership. One would think it would be possible to raise a modest amount of sensible finance against the GE revenue stream or to find an industry partner who is prepared to finance this. With all of that said, I think it is safe to conclude that 9.5p per share significantly undervalues the business in almost all scenarios. |
Posted at 09/2/2024 10:04 by bmcollins @bamboo@40f I don't wish to sound like an echo chamber here but with that update and given the recent weakness of the share price I am a little bemused as to why there has been so little reaction, i.e. no change in the 8.5p-9p price and very few, only small trades done as well. I guess it is better than the 10% to 20% mark-downs many AIM shares have suffered after their updates recently but I read a lot of good news in their RNS today. I'm pretty much up to my maximum in what I'd ever put into a stock of this nature but with profitability apparently very close, GEHC & Gates foundation backing it, to me the upside looks much more likely than the downside so I'm seriously thinking about breaking one of my own rules and doubling up. |
Posted at 08/9/2023 01:13 by bamboo2 hi, 40F, I bought into DNL last Summer 2022 for the t/o potential and a t/o was announced 30/8/2022.Co-incidentally, it shared the IPGroup stable with IUG, and as we know, in recent years IPGroup always seem ready to do a deal. Like IUG, DNL was too, on the cusp of becoming profitable. The DNL share price had been 11.25, the offer was 27.5p [premium approx 150%]. I reckon if we worked on that kind of basis, we'd be in the right ball park. IUG 11 x 150% = 27.5p Further info... |
Posted at 07/9/2023 23:15 by 40 fathoms I think it all depends as we are prisoners to our share price. In the end any offer will be a function of share price at the time and not necessary a reflection of true value.Assuming the companies evolution of revenue and profit comes to pass, I think an offer today would come at about 20p, this would be 30p this time next year. I think in 2025 or 2026 it starts to get interesting as you would then expect the share price to reflect the fact that we would be significantly profitable, with a clear path to GBP 10 million of annual profit and plenty of growth still to come from product development and products under development. I think then an offer would come at well north of 60p. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
